Бизнес••NEXORA Editorial•TechCrunch
Enveda raises $311 million to advance nature-derived AI drugs into clinical trials
Summary
Enveda has secured $311 million to advance more drugs based on nature-derived compounds and developed with the help of artificial intelligence into clinical trials. The funding will support the next stage of development for these therapies.
Details
Enveda has raised $311 million to develop more drugs based on nature-derived compounds and created with the help of artificial intelligence. The funding is intended to help move these medicines into clinical trials.
The financing highlights the use of natural sources and artificial intelligence technologies in the process of discovering and developing drugs.
Enveda plans to direct the capital toward its drug development programs so that more of them can reach the clinical-trial stage. The information provided does not specify the terms of the financing, the number of projects involved, or their therapeutic areas.
The company describes the funding as a resource for expanding its portfolio of nature-derived medicines. The next stated step for these developments is to advance them into trials involving humans.
NEXORA AI — Why it matters
The funding could enable Enveda to move more nature-derived, AI-assisted drug candidates into clinical development.
NEXORA PRO
Unlock detailed analysis, key facts, context, story developments, source comparisons, a personalized feed and smart alerts.
Explore NEXORA PRO